Agenus Stock Scheduled to Reverse Split on Friday, April 12th (NASDAQ:AGEN)

Shares of Agenus Inc. (NASDAQ:AGEN) are scheduled to reverse split on Friday, April 12th. The 1-20 reverse split was announced on Friday, April 12th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 12th.

Agenus Stock Performance

AGEN stock traded down $0.04 during midday trading on Monday, reaching $0.47. The company’s stock had a trading volume of 26,355,944 shares, compared to its average volume of 10,497,963. The stock has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $0.76. Agenus has a 1 year low of $0.41 and a 1 year high of $2.13. The firm has a market capitalization of $195.01 million, a price-to-earnings ratio of -0.66 and a beta of 1.26.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $54.21 million. As a group, analysts forecast that Agenus will post -0.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on AGEN shares. HC Wainwright restated a “buy” rating and set a $8.00 price target on shares of Agenus in a research note on Thursday, March 14th. B. Riley cut their price target on Agenus from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Monday, March 18th. Finally, StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Sunday, March 24th.

Insider Buying and Selling at Agenus

In other Agenus news, insider Garo H. Armen purchased 500,000 shares of the stock in a transaction on Thursday, February 15th. The stock was acquired at an average price of $0.65 per share, with a total value of $325,000.00. Following the completion of the acquisition, the insider now owns 625,969 shares in the company, valued at $406,879.85. The acquisition was disclosed in a filing with the SEC, which is available at this link. 4.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Agenus

Institutional investors have recently added to or reduced their stakes in the business. U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Agenus during the first quarter worth about $25,000. Commonwealth Equity Services LLC acquired a new stake in shares of Agenus during the third quarter worth about $26,000. Sei Investments Co. acquired a new stake in shares of Agenus during the first quarter worth about $28,000. SG Americas Securities LLC acquired a new stake in shares of Agenus during the third quarter worth about $36,000. Finally, Two Sigma Securities LLC lifted its holdings in shares of Agenus by 116.9% during the second quarter. Two Sigma Securities LLC now owns 22,750 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 12,263 shares during the period. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.